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INTRODUCTION 
Toxoplasmosis is the most common cause of posterior uveitis in the 
immunocompetent  individuals. It is estimated that at least 500 million 
people worldwide are infected with this organism. In the developing world 
its prevalence is probably underestimated. Traditionally  thought  to be a 
self-limiting retinochoroiditis, ocular toxoplasmosis can cause sight 
threatening complications .In infants  and in immunosuppressed individuals 
it can be associated with potentially  fatal  systemic toxoplasmosis.Earlier 
believed to be mostly a reactivation of infection acquired in utero, evidence 
shows that acquired infection is more common than previously thought. It is 
one of the few uveitides for which we can potentially make a definite 
diagnosis. The  host – organism interrelationship  has a influence on the 
disease manifestations. A variety of diagnostic  and  therapeutic measures 
are being  researched to aid in managing the disease. 
 
EPIDEMIOLOGY 
An estimated half of the world’s population is infected with 
toxoplasmosis. It is believed to affect at least 10% of the adults in the 
northern temperate countries and more than half the people in the 
mediterranean and the tropical nations. 20 -70% of the general population 
has a positive serology for the organism. 
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TOXOPLASMA  GONDII- THE ORGANISM 
It is an obligate intracellular parasite ,ubiquitous in nature  ,being 
found all over the world.It belongs to phylum -Apicomplexa,class –Sporozoa 
and order – Eucoccidia. The  definitive  host of this organism are the 
members of the cat family and  intermediate hosts are human beings, 
livestock and rodents. 
 
The parasite is known to exist in three forms which include  
tachyzoite, bradyzoite  and  oocyst.  
 
Tachyzoites  are crescent shaped structures ,6-7 microns in length. 
They are the invasive form of the organism which multiply into daughter 
cells and result in the acute manifestations of the disease. They are 
disseminated throughout the body in the macrophages via lymph and blood 
and can penetrate virtually any nucleated cell. In the cell cytoplasm, the 
organism resides in a parasitiphorous vacuole which protects it. 
 
Bradyzoites  are the encysted form of parasite found within tissue 
cysts in structures like brain, heart and retina. It is found in  vacuoles 
surrounded by cell membrane elaborated by the host, which protects it from 
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the host’s immune reaction. When the cyst wall breaks down, bradyzoites 
develop into tachyzoites and lead to reactivation of infection. 
Oocysts are oval in shape, 10-12 microns in length and found uniquely in the 
intestinal mucosa of cats. It is the product of sexual reproduction and shed in 
cat faeces. It can remain viable in soil for more than an year. Sporulation 
creates the infectious  oocyst  containing sporozoites which is ingested by 
cats and human beings where it multiplies in intestinal epithelial cells and 
produces tachyzoites. 
 
Many of the antigens associated organism have been identified.  SAG 
1 or p30 is perhaps the most studied of the antigens and plays a role in the 
organism’s ability to invade a cell. It is useful in the serological diagnosis of 
infection. SAG 2 or p22 is a cell surface antigen which can participate in 
antibody dependent, complement mediated lysis of tachyzoites. Another  
antigen is F3G3, antibody  to which has been suggested to have the ability to 
confer passive immunity. These antigens could be used as a basis for vaccine 
development ,in that immunization against these antigens might abrogate 
rapid entry of tachyzoite into the cell. 
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LIFE CYCLE OF TOXOPLASMA 
It can be divided into two stages, feline and non feline 
Non feline – This is the stage the parasite spends in the intermediate 
hosts i.e human beings, mouse, sheep and pigs. These acquire infection by 
ingesting tissue cyst containing  bradyzoite from raw or undercooked meat 
or the sporulated oocyst from ingesting contaminated soil. The cyst is 
digested by the acidic pH gastric secretion which releases bradyzoites or 
sporozoites. These enter the host’s intestinal epithelium and transform into 
rapidly dividing tachyzoites. The tachyzoites  attach to the host cell and form 
a parasitiphorous vacuole ,within which it divides. Finally ,the host cell 
ruptures, releasing parasites that infect the adjoining cells. Released 
tachyzoites can undergo two fates. They can be eliminated by the host’s 
immune response by induction of parasitidal antibodies, activation of 
macrophages, interferon gamma production and  stimulation of CD 8 
lymhocytes. Some transform into tissue cysts containing bradyzoites which 
lodge into the CNS, muscles and the eye. 
 
Feline – Cat ingests tissue cysts containing bradyzoites which undergo 
several intermediate stages and lead to the production of gametes. The 
gametes fuse with each other to form a zygote , which envelopes itself in a 
rigid wall and is secreted in the feces as an unsporulated oocyst. The oocyst 
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after 2-3 days of exposure to ambient temperature undergoes sporulation to 
form sporozoites. The sporulated oocysts may be ingested by the 
intermediate hosts and the lifecycle thus continues. 
 
MODES OF TRANSMISSION OF INFECTION 
Humans acquire the infection in a number of ways. Most often it is by 
eating the meat of infected animals containing the tissue cysts, particularly   
undercooked  pork, and less commonly lamb, beef and chicken. Infection 
can also spread by coming in contact with contaminated cat faeces while 
handelling cat litter, consumption of unpasteurized goat milk, unwashed 
fruits and vegetables and inhalation of sporulated oocyst. 
 
Congenital infection occurs due to transplacental spread of the 
organism. It is a feature of newly acquired infection in the mother and not of 
chronic infection.  Primary maternal infection has been estimated to occur in 
0.2-1% of pregnancies . The rate of congenital toxoplasmosis increases from 
10-15% due to infection in the first trimester to 60% due to infection in the 
third trimester. Early trimester infection results in more severe infection with 
higher chances of spontaneous abortion. 
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OCULAR TOXOPLASMOSIS – PATHOGENESIS 
The disease manifestations are controlled by the host’s immune 
response to infection. The  primary pathological  finding is a coagulative 
retinal necrosis. Toxoplasma tachyzoites infect  the retina causing an intense 
mononuclear inflammatory reaction in the retina and vitreous, whereas a 
granulomatous  reaction usually occurs in the contiguous choroid. Vitritis 
and anterior uveitis  may represent a hypersensitivity response. 
 
Cysts on the other hand can persist for years in the tissue without 
inciting any response due to the presence of a host elaborated cell membrane. 
Nearly two third of the patients present with relapses. There are two main 
theories postulated to justify this .The first states that the dormant cysts 
rupture in times of immunosuppression or stress releasing T. gondii 
organisms which may either actively invade the retina or stimulate an 
inflammatory retinochoroiditis. The second theory states that it is an 
autoimmune  response to the retinal antigens like the S- antigen that incites 
the retinochoroiditis.28 
 
Humoral immunity can play a role in the lysis of organism when it is 
extracellular and antibody coated parasite may not form a protective 
membrane which is essential for its survival in the macrophage.  
15 
 
However it is the cell mediated immune response which is of prime 
importance in  the host defense mechanism .Both CD4  and  CD8 cells play a 
role. An autoimmune mechanism has been postulated too, wherein  
inflammation is initiated  by the destruction of the retina by the parasite and 
subsequent sensitization  to the uveitogenic antigen.  
 
Host’s  Immune  Response 
The disease manifestation depends on the strain of Toxoplasma and 
the host’s immune response. In evaluating 28 strains from around  the world, 
Sibley and Boothroyd found that virulent strains had the same genotype 
while the non virulent strain were polymorphic, implying that specific strains 
were more likely to cause the disease.    
 
The  host’s immune response   is an important feature and determines 
the disease manifestations. When Toxoplasma organism passes through the 
digestive tract and finally enters the host cell , it does so at the gut mucosal 
level. This evokes the production of IgA antibody ,which is a modulator of 
protection and an indicator of infection. Also, titres of IgA against p30(SAG-
1) are a useful marker of congenital and acute toxoplasmosis. 
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However, if the parasite evades the mucosal response, humoral and 
cell mediated immunity are activated. Humoral immunity induces the 
formation of IgM and IgG  antibodies, which kill the parasite by various 
mechanisms, especially when extracellular. 
 
Cell mediated immunity is the main protective response evoked by the 
parasite during infection. Antibody opsonized  parasites are  phagocytosed 
by macrophages, which leads to activation of macrophages. These kill the 
parasite by oxygen dependent and oxygen independent mechanisms. T cells 
activated by various parasite antigens lead to the production of various 
cytokines, the important ones being Interleukin -4(IL – 4) and Interferon 
gamma(IFN – gamma).These aid in the killing of the parasite.Also,CD4 and 
CD8 cells are cytolytic against parasite infected macrophages. 
 
Immune Response In The Immunocompromised 
Here, both cell as well as humoral mediated immunity is altered. Due 
to the decreased  number of the helper T cells, there is no observed increase 
in antibody titres during exacerbation of infection. T-cells fail to secrete 
IFN- gamma and IL-2, which can result in persistence of infection. 
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CLASSIFICATION 
Toxoplasmosis can be broadly classified into Congenital and Acquired 
forms.   
 
CONGENITAL TOXOPLASMOSIS 
It  occurs due to transplacental  spread of infection. If occurring in the 
first trimester , there is a 15-20% incidence of  infection. Stillbirth, abortion 
and congenital anomalies are common. If occurring  in the third trimester, 
there is a 40% incidence of infection  which is often subclinical and less 
severe. Chronic maternal infection is not associated with congenital disease. 
More than 82% of congenitally infected individuals not treated as infants 
will develop retinal lesions by the time they reach adolescence.29 
 
The most common manifestation of congenital toxoplasmosis is 
retinochoroiditis. Bilateral chorioretinal scars are seen in almost 80% of 
patients with congenital toxoplasmosis with a prediliction for the macula. 
This could be attributed to the theory of earlier vascularisation of the 
posterior pole than the periphery during development and the fact that fetal 
vasculature contains end arterioles. Another theory is that the parasite 
probably invades the eye through the Posterior Ciliary  artery or the Optic 
nerve.30 The retinal lesion tends to be self limited usually. Other ocular 
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manifestations include microcornea, microphthalmos, nystagmus and 
strabismus. 
 
Acute congenital toxoplasmosis is a systemic disease with more 
serious implications. It is usually associated with low birth weight, fever, 
jaundice, maculopapular rash,  pneumonia and hepatosplenomegaly. CNS 
involvement implies poor outcome and may result in microcephaly, 
hydrocephalus, seizures, disseminated intracranial calcification and 
psychomotor retardation. The classical triad of congenital toxoplasmosis 
consists of chorioretinitis, convulsions and intracranial calcification. Anti 
toxoplasma immunoglobulins (IgM) is present in 75% of infants with 
congenital  toxoplasmosis. 
 
ACQUIRED TOXOPLASMOSIS 
It results commonly due to ingestion of tissue cysts from contaminated 
beef, lamb, pork or due to ingestion of oocysts from soil and vegetables. 
Rarely blood transfusions and accidental laboratory inoculation also result in 
infection.  Usually subclinical and asymptomatic, about 10 – 20% of the 
cases can develop symptoms. These consist of fever, myalgia, 
lymphadenopathy and maculopapular rash sparing palms and soles. The 
disease is benign and self limited in immunocompetent individuals. Contrary 
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to the earlier belief that only 1-3% of these cases develop ocular 
manifestations, serologic studies reveal that ocular toxoplasmosis is more 
frequently associated with acquired disease. The retinochoroidal lesions are 
not associated with old scars in these cases.  
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CLINICAL FEATURES OF OCULAR TOXOPLASMOSIS 
 
Patients usually present with unilateral  reduction in visual acuity, 
floaters , metamorphopsia  or  may be  asymptomatic. The  classical clinical  
signs are as described below. 
 
• Anterior segment:  Either granulomatous or non granulomatous  
inflammation may be present. Therefore either fine or mutton fat keratic 
precipitates may be seen behind the cornea. Anterior chamber activity  is 
detected in the form of cells and flare using a 1 x 1 mm slit beam. 
Sometimes there may be no evidence of AC activity. The grading system 
for cells and flare is given below. 
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Grading of  AC cells : SUN 2005 Am J Ophthalmol 2005;140:509 
 
                      
 
 
  
 
 
  
 
 
Grading of  AC flare : SUN 2005 Am J Ophthalmol 2005;140:509 
 
Grade 
 
Description 
 
0  
  
none 
 
1+                          Faint 
 
2+ Moderate(iris and lens clear) 
 
3+ Marked(iris and lens hazy) 
 
4+ Intense(fibrin or plastic aqueous) 
 
Activity                   Cells 
0 <1 
0.5+ 1-5 
1+ 6-15 
2+ 16-25 
3+ 26-50 
4+  >50 
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 Vitreous : Usually severe vitritis especially overlying the lesion may be 
seen. Inflammatory cells may be see floating in the vitreous cavity and 
require a Hruby or a contact lens for visualization and grading. However 
vitreous haze is a better indicator of active inflammation than vitreous 
cells because it combines the optical effect of cellular infilteration and 
protein leakage. It can be graded with the help of a scale based on the 
view of the optic disc and posterior retina with the help of the indirect 
ophthalmoscope and a 20 diopter lens and comparison of the view with a 
standard photograph (Nussenblatt’s method). This makes the system 
more reproducible than the other subjective grading systems. 
 
 Retina : The organism’s  propensity  to involve the neural tissue leads to 
a retinitis and secondary choroiditis. An area of active retinitis consisting 
of an oval or circular cream coloured lesion adjacent to an old atrophic  
chorioretinal scar is seen typically. There may be areas of haemorrhage in 
the region surrounding the active retinitis. Sheathing  of blood vessels 
may be there. 
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3 morphological variants of the retinal lesion have been described 
LARGE 
DESTRUCTIVE 
LESION 
INNER PUNCTATE 
RETINAL LESION 
OUTER PUNCTATE 
RETINAL LESION 
Dense yellow white 
elevated lesion, >1 DD 
Single/multiple  areas of 
active retinitis 
associated with mild 
retinal oedema 
Multiple gray white 
punctuate lesions at the 
level of RPE or deep 
retina 
Associated with anterior 
uveitis and dense vitritis 
Associated with mild 
vitreous reaction 
Little  or no vitreous 
reaction 
Most common and  
serious variant 
  
Requires treatment 
irrespective of location 
Requires  treatment if 
present at macula 
Resolves slowly and 
can recur in a satellite 
fashion 
 
 
 Papillitis 
 Rarely scleritis 
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The reasons for reduction in visual acuity in these cases are: 
 
• Vitritis 
• Lesions  situated  at the posterior pole with oedema and inflammation 
• Lesions involving the macula 
 
        Complications   associated due to ocular toxoplasmosis may be: 
 
• Chronic  iridocyclitis 
• Cataract 
• Retinal detachment 
• Consecutive optic atrophy 
• Choroidal neovascular  membrane 
• Branch retinal vein occlusion 
• Secondary glaucomas 
• Band keratopathy 
• Cystoid macular oedema 
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Toxoplasmosis in the Immunocompromised 
 
In the immunocompromised and elderly, ocular toxoplasmosis can be 
quite  serious but more importantly, can be associated with fatal systemic  
infection. Toxoplasmosis may involve  CNS, heart and lungs in patients who 
have undergone organ transplantation and in patients with lymphomas. In 
patients who have AIDS, ocular toxoplasmosis is less common than that of 
the CNS. The salient features of ocular toxoplasmosis in an AIDS patient are 
as follows: 
 
 
 Usually the result of  a newly acquired infection or disseminated 
infection unlike in an immunocompetent  patient where it is mostly a 
reactivation of congenital infection. 
 Extensive confluent areas of retinitis – usually greater than 5 DD. 
 Bilateral  disease -18-38% of the cases 
 Solitary ,multifocal or miliary pattern 
 Lower degree of vitritis than in an immunocompetent patient. 
 Pre existing  scars  may be absent ,therefore  diagnosis may be  
difficult. 
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 Usually progressive unlike in an immunocompetent patient,  
therefore a  prompt  diagnosis is necessary. 
 Patient may have associated cerebral or disseminated  toxoplasmosis, 
therefore a thorough evaluation is necessary. 
 Ig M titres may not be detectable and Ig G may not  rise. Therefore  
diagnosis  can be confusing. 
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DIFFERENTIAL DIAGNOSIS –OCULAR 
TOXOPLASMOSIS 
 
 Acute Retinal Necrosis 
 Pars planitis 
 Sarcoidosis 
 Endogenous bacterial or fungal infection 
 Syphilis 
 Tubercular chorioretinitis 
 Intraocular lymphoma 
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  
INVESTIGATIONS 
 
 SEROLOGY 
The diagnosis of ocular toxoplasmosis is always based on a 
compatible fundus lesion and  supported by a positive serology for 
antibodies. 
 
The significance of each type of antibodies are as follows: 
 IgG – It appears after 2 weeks, peaks at 2 months and then persists in 
low titres throughout the life of the individual. 
 IgM – It appears transiently within two weeks of infection and then 
disappears. 
 IgA – It persists only for seven months. 
 
             The diagnosis of the disease by serologic means alone is not yet 
feasible, as emphasized by a study performed by Rothova and coworkers. 
They noted that even though IgG antibody positivity was seen in 100% of 
their patients with clinically apparent toxoplasmosis,58% of the control 
subjects also showed positive results. Phaik and coworkers estimate that at 
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least 77% of those with ocular toxoplasmosis had serotitres equal to or 
greater than 1:256,somewhat higher than those found in control subjects. 
Antibody titres do not correlate with ocular disease .Antitoxoplasma 
antibodies may be in very low titres and preferably should be tested in 
undiluted titres(1:1). 
 
Nonetheless most believe that the diagnosis is very much a clinical 
one, with serologic findings being supportive but not definitive. 
 
The serological tests for toxoplasmosis are classified as follows: 
• Sabin Feldman test 
• Indirect fluorescent antibody test 
• Indirect haemagglutination test 
• Complement fixation test 
• ELISA 
 
Sabin Feldman test :   It is the gold standard and reference test for ocular 
toxoplasmosis.It is both highly sensitive and specific. Here live toxoplasma 
organisms are taken and mixed with test serum and complement. Serial 
dilutions are made and the titre at which more than 50% organisms are 
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unstained is considered. A titre of 1:4 is considered positive. This test does 
not correlate with the severity of the disease. 
Indirect fluorescent antibody  test :  Here killed tachyzoites are mixed 
with patient’s serum and fluorescein tagged antihuman serum against IgG or 
IgM.A  titre  of 1:8 is considered positive.It is useful in cases of acute and 
congenital disease.ANA and RF positivity may give false positive results. 
 
Indirect haemagglutination test : It involves coating  of lysed organisms 
onto red blood cells which are then exposed to the patient’s serum;positive 
sera cause the RBC’s to agglutinate. This becomes positive 2-4 weeks after 
infection and is more useful for screening purposes. 
 
Complement fixation test : In this test a titre of 1:4 is considered positive 
and a titre of >1:32 indicates recent infection. 
 
ELISA : This involves binding of the patient’s antibodies to an excess of 
solid phase antigen. The complex is then incubated with an enzyme linked 
second antibody. Assessment of the enzyme activity provides measurement 
of the specific antibody concentration. This is a sensitive test used to detect 
IgG and IgM antibodies and can also be used to detect antibodies in the 
aqueous which are more specific than those of the serum. 
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 PCR 
In individuals in whom toxoplasmosis is considered a diagnostic 
possibility but the presentation is atypical, Polymerase chain reaction of the 
organism’s DNA is a useful diagnostic aid.17 This can be done from ocular 
tissue sections or the aqueous humor. 
 
Witmer Goldmann coefficient – This is the ratio of antibodies against 
Toxoplasma in the aqueous to that in the serum.It can be used to evaluate the 
intraocular antibody production. 
 
 IMAGING STUDIES 
FFA:  Fundus fluorescein angiography shows hypofluorescence in the early 
phase followed by progressive hyperfluorescence secondary to leakage. 
 
ICG: Indocyanine green angiography of  active lesions are mostly 
hypofluorescent.Images not picked up by clinical examination or FFA are 
sometimes seen with ICG. 
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OCT: Optical Coherence Tomography is helpful in identifying potential 
complications, including epiretinal membrane, cystoids macular edema, 
vitreoretinal traction bands and choroidal neovascularization. Active lesions 
are depicted by a highly reflective intraretinal area corresponding to the area 
of retinitis and which also shadows the underlying choroid. The posterior 
hyaloid is thickened and detached over the lesion.8 
 
USG B-Scan: It is indicated in the prescence of ocular media opacities 
especially in the vitreous.The most common findings include intravitreal 
punctiform echoes, thickening of the posterior hyaloid, partial or total 
posterior vitreous detachment and focal retinochoroidal thickening. 
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TREATMENT 
Toxoplasma retinochoroiditis in an immunocompetent individual is 
often a self limited process. Therefore not every case of ocular 
toxoplasmosis requires treatment. The potential benefits of treatment need to 
be weighed against the risks associated with antimicrobial therapy.The 
inability of most of the current drugs to eliminate cysts and prevent 
recurrences should be kept in mind too. 
 
Treatment is always warranted in case of congenital toxoplasmosis 
and in the immunocompromised. In case of toxoplasmosis in the 
immunocompetent ,opinion varies amongst practitioners. In 1991 Engstorm 
and associates conducted a survey of all physician members of the American 
Uveitis Society to determine the current practices in the management of 
ocular toxoplasmosis. Among the respondents only 5% treated all active 
lesions regardless of ocular findings. Majority agreed to treat in case of. 
 
• Decreased visual acuity 
• Macular or peripapillary lesions 
• Lesions >1DD in size 
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• Lesions associated with moderate to severe vitritis 
• Presence of multiple active lesions 
• Persistence of active lesions for more than 1 month 
• Any ocular lesion associated with recently acquired infection 
 
  The aims of treatment are 
• To decrease the duration and severity of acute inflammation 
• To lessen the risk of permanent visual loss by decreasing the size of 
the eventual chorioretinal scar 
• To reduce the risk of recurrences 
 
 There are a variety of drugs used in the treatment of ocular 
toxoplasmosis.  Each of these is discussed briefly below. 
 
• Pyrimethamine – It belongs to the diaminopyramidine group.A potent 
inhibitor of dihydrofolate reductase ,it thereby inhibits folic acid 
metabolism. Human beings can utilize exogenous folinic acid  for their 
cells ,unlike T.gondi. It is given as 75 mg PO loading dose followed by 
Dosage - 25 mg PO b.d dose. It has been shown to limit the size of the 
retinochoroidal scar in patients with toxoplasmosis.19 
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Interactions– Concurrent use with other antifolate agents like 
Methotrexate may result in bone marrow suppression.It should be 
discontinued if signs of folate deficiency develop.  
Contraindications – Documented hypersensitivity, Megaloblastic anemia 
resulting from folate deficiency.  
Precautions – Dose to be reduced or discontinued if signs of folate 
deficiency develop, depending on the patients response. Caution to be 
exercised in case of hepatic or renal impairment. May precipitate 
hemolytic anemia in a case with G-6-PD deficiency, especially under 
stressful conditions. In pregnancy fetal risk revealed in animal studies, 
but not established in humans. May be used if benefits outweigh the fetal 
risk. 
 
• Sulfadiazine – Member of sulfa group of drugs. Exerts  bacteriostatic 
action through competitive antagonism of  PABA(para amino benzoic 
acid) and therby hampers folate metabolism.  
Dosage – 2 g  p.o  o.d loading dose followed by 1 g q.i.d 
Interactions – Increases the effect of oral anticoagulants and oral 
hypoglycemic agents. Effects of Sulfadiazine are decreased when 
administered along with PABA or PABA metabolites eg.Procaine, 
Proparacaine and Tetracaine.  
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Contraindication – Documented hypersensitivity   
Precautions – Adverse effects include skin rash and renal crystallization, 
which can be avoided by a large intake of fluids. Treatment should be 
stopped if hematuria, albuminuria or crystalluria develops. Caution in 
impaired renal, hepatic function and in G-6-PD deficiency. Fetal risks 
revealed in animals but not documented. 
 
• Trimethoprim  and Sulfamethoxazole – Exerts bacteriostatic action 
through competitive antagonism with PABA.Regular strength tablets 
contain 80 mg Trimethoprim and 400 mg Sulfamethoxazole while double 
strength contains 160 mg and 800 mg of each respectively. 
Dosage -960 mg B.d  
Interactions – Coadministration with Warfarin may increase PT,with 
diuretics increases the incidence of thrombocytopenic purpura in the 
elderly, potentiates bone marrow depression with Methotrexate and 
hypoglycemic response with Sulfonylureas.  
Contraindications – Documented hypersensitivity, Megaloblastic anemia 
secondary to folate deficiency and during breastfeeding. 
Precautions – Discontinue at the first appearance of skin rash or 
significant hematologic changes occur. Goitre, dieresis and hypoglycemia 
may occur with Sulfonamides. Prolonged high doses may cause bone 
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marrow suppression which should be treated with 5-15 mg/d of Inj. 
Leucovorin. Caution to be exercised in patients with folate deficiency, 
with G-6-PD deficiency and in patients with AIDS, renal or hepatic 
impairment. 
 
• Clindamycin – Belongs to the macrolide group and inhibits bacterial 
growth possibly by blocking the dissociation of peptidyl-t RNA from 
ribosomes, thereby arresting protein synthesis. Some animal evidence 
exists to show that Clindamycin helps in the eradication of the encysted 
form.  
Dosage – 300 mg  p.o  q.i.d 
Interactions – Increases the duration of neuromuscular blockade by 
Tubocurare  and  Pancuronium. Effects antagonized by Erythromycin and 
absorption delayed with concomitant antidiarrhoeal administration. 
Precautions – Can possibly cause severe colitis due overgrowth of 
Clostridium difficile. Caution in hepatic impairment. 
 
• Atovaquone – It is a hydroxylnapthaquinine that inhibits the 
mitochondrial   electron transport chain by competing with ubiquinone at 
the ubiquinone – cytochrome- reductase region (complex III). The 
inhibition of electron transport by Atovaquone will result in the inhibition 
38 
 
of nucleic acid ATP synthesis in the parasite. It has also shown activity 
against bradyzoites in the animal models of  toxoplasmosis. 
Dosage – It can be given as 750 mg qid  PO. 
Interactions – It may increase the serum levels of Zidovudine. 
Coadministration with Rifampicin may result in decreased levels of 
Atovaquone. It may decrease the serum levels of  TMP-SMZ. 
Contraindications – Documented hypersensitivity. 
Precautions – Caution to be exercised in elderly patients and in those 
with hepatic and renal impairment. 
 
• Spiramycin - Macrolide antibiotic, thought available for quite a long 
time, has been used only sporadically. Resembles erythromycin in 
properties and spectrum of action. 
Distinctly has been found to limit risk of transplacental transmission of 
Toxoplasma infection.  
Use – specific utility for toxoplasmosis and recurrent abortions in 
pregnant women. 
Dose – 3 week courses of 3 MU tid repeated after 2 weeks gap till 
delivery.  
Side effects – Gastric irritation, nausea, diarrhoea, rashes  
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DRUG 
GROUP 
MECHANISM OF 
ACTION 
DOSAGE SIDE EFFECTS
PYRIMETHAMINE 
Diaminopyramidine 
-Inhibits folic acid 
metabolism 
75 mg o.d(LD) 
25 mg b.d(MD) 
Bonemarrow 
suppression 
GI intolerance 
SULFADIAZINE 
Sulpha group 
-Inhibits folic acid 
metabolism 
2 g o.d(LD) 
1 g q.i.d (MD) 
Skin rashes 
Renal 
crystallisation 
CLINDAMYCIN 
Macrolide 
-Inhibits peptide 
chain elongation 
300 mg q.i.d 
Pseudomembran
ous colitis 
COTRIMOXAZOLE 
Trimethoprim and 
Sulfamethoxazole 
960 mg b.d 
Skin rashes 
Crystalluria 
SPIRAMYCIN Macrolide 400 mg t.i.d Gastric irritation 
MINOCYCLINE 
Semisynthetic 
Tetracycline 
-Inhibits 30s 
ribosome during 
protein synhesis 
100 mg b.d 
Phototoxicity 
AZITHROMYCIN 
Macrolide 
500 mg b.d 
Gastric irritation 
ATOVAQUONE 
Antimalarial 
750 mg q.i.d 
Rashes 
GI upset 
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COTICOSTEROIDS 
Corticosteroids have a role to play in the treatment of ocular 
toxoplasmosis.   
 
Topical steroids may be used to curtail anterior chamber inflammatory 
reaction. Oral steroids are used to treat the inflammation associated with 
vitritis, vasculitis and macular edema. Since increased ocular inflammation 
and retinal necrosis may be seen in patients receiving oral steroids without 
antimicrobial therapy, it is recommended to start the latter at least 24 hours 
before the former . 
 
Oral steroids should be tapered before discontinuing the antimicrobial 
treatment. In  immunocompetent  individuals treatment is continued till there 
is significant decrease in inflammation  active. This is typically in the range 
of 4-6 weeks but occasionally may be longer. Depot steroid therapy is 
absolutely contraindicated in the treatment of ocular toxoplasmosis. The high 
dose medication in close proximity to the ocular tissues apparently 
overwhelms the host’s immune response, leading to rampant retinal necrosis 
and potential for a blind ,phthisical globe. 
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CYCLOPLEGICS 
These have a role to play in case of anterior uveitis. They help by 
• Reducing ciliary spasm and the pain associated with it. 
• Breaking the formed posterior synechiae. 
• Preventing the formation of posterior synechiae further.                    
Examples include 1%Atropine eyedrops or ointment, 2% Homoatropine 
eyedrops and 0.5% , 1% Cyclopentolate. 
 
Precautions – Caution to be maintained in  patients with a raised intraocular 
pressure. It can also cause toxic systemic anticholinergic effects when used 
in children, especially in infants. Compressing the lacrimal sac digitally for 
1-3 mins after instillation may minimize systemic absorption. 
 
There are 2 standard regimes for the treatment of ocular 
toxoplasmosis. These are the triple and the quadruple regimes. The former 
consists of Pyrimethamine in conjunction with Sulfadiazine and oral 
corticosteroids while the latter includes Clindamycin additionally. Folinic 
acid is administered concurrently with Pyrimethamine to prevent bone 
marrow suppression. A baseline blood count should be obtained before 
initiating treatment followed by weekly measurements to monitor for drug 
toxicity. Therapy should be discontinued if the WBC count falls below 
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4000/cc, platelet count below 100,000/cc or if either decreases 25-50% 
below the baseline. Rothova and associates found a relationship between 
treatment with Pyrimethamine and Sulfadiazine and reduction of lesion size. 
The search for better and less toxic antparasitic drugs has yielded 2 serious 
candidates, Atovaquone and Azithromycin both of which have exhibited in 
vitro and in vivo efficacy not only against tachyzoites but also against cystic 
forms of Toxoplasma25 
 
During pregnancy Spiramycin is thought to be a safe drug and may 
reduce the rate of Toxoplasma transmission to the fetus. Other alternative 
drugs that have been used are Sulfadiazine and Pyrimethamine, but they are 
associated with several side effects and are best avoided.In a study carried 
out on Callomys callosus sp. of mice Azithromycin was shown to prevent 
the occurrence of congenital toxoplasmosis, but this remains to be proven in 
human beings.15 
 
In the immunocompromised because of progressive nature of ocular 
disease treatment is recommended when there is active disease. The 
possibility of bone marrow suppression with pyrimethamine and  
corticosteroids are  of concern.  Long term maintenance therapy with 
clindamycin needed to prevent recurrence.  
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Genotypic strains of Toxopasma gondii and resistance to medication 
were recently suspected. Despite the fact that all lineages can infect human 
beings, type II strains are predominant in Europe and North America, type 
III strain and recombinant type I/III are more common in South America. 
Type I is highly virulent, type III strains of the intermediate type and typeI/II 
are nonvirulent. A recent paper of Pascale Meneceur et al has shown no 
significant difference in response of  type I/II/III  towards Pyrimethamine, 
Sulfadiazine  and Atovaquone therapy. 
 
SURGICAL TREATMENT 
Surgical treatment including photocoagulation, cryotherapy and 
vitrectomy has been tried, but efficacy not clearly demonstrated. The 
potential for retinal or vitreous hemorrhage and even retinal detachment 
when treating an acutely inflamed retina makes surgical intervention less 
desirable in active disease. Also, given that normal appearing retina can 
harbor Toxoplasma cysts, the above procedures cannot predictably prevent 
disease recurrence. 
 
Pars plana vitrectomy may be indicated in cases of retinal detachment 
secondary to vitreous tractions  or when vitreous opacities are present. 
44 
 
However treatment with antimicrobial agents is indicated before and after 
surgery.  
 
Role Of  Azithromycin 
It belongs to the macrolide group which also includes Erythromycin 
and Clarithromycin. Its structure consists of a large lactone ring to which 
sugars are attached. 
Dosage – Max adult dose – 2000 mg/day  
       Max pediatric dose – 20-30 mg/kg/day 
Mechanism of action – It binds specifically to 50s subunit of ribosome thus 
inhibits peptide chain elongation, and thereby inhibits bacterial protein 
synthesis. 
 
Pharmacokinetics – The remarkable properties of Azithromycin are 
acid stability, rapid oral absorption, marked tissue distribution and 
intracellular penetration. Particularly high concentrations are obtained inside 
macrophages and fibroblasts. It is largely excreted unchanged in bile, renal 
excretion is less than 10%. 
 
Spectrum of action – It is similar to the other macrolides, but is less 
active against gram positive cocci and more active against H.influenzae. It is 
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highly active against Legionella, Mycoplasma, Campylobacter, Chlamydia 
and Moraxella. 
 
Growing evidence of  data suggests that the drug Azithromycin also 
has anti inflammatory activity through inhibition of transcription factor NF – 
Kb. The anti inflammatory potency is about 4 times weaker than 
hydrocortisone and 14 times weaker than dexamethasone.31  
 
Uses of Azithromycin – 
It is the drug of choice in Legionnaire’s pneumonia and infections due 
to Chlamydia trachomitis. Other indications are pharyngitis, tonsillitis, otitis 
media, pneumonias, Streptococcal and some Staphylococcal skin infections. 
Malaria and toxoplasmosis are also its potential indications. 
 
Drug interactions – Azithromycin has been found not to interact with 
hepatic CYP3A4 enzyme. Interaction with terfenadine, warfarin, 
carbamazepine and theophylline is not likely, but not totally ruled out. 
 
Adverse reactions – Serious adverse effects are rare. Most of the side 
effects are gastrointestinal and include nausea, vomiting and diarrhea. These 
can occur equally for oral as well as intravenous formulations. 
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In  ocular toxoplasmosis , its action is perhaps inhibition of protein 
synthesis .In vitro and in vivo efficacy against toxoplasma gondii has been 
reported,with an effect on the cystic form if administered for longer than 4 
weeks20. Also Atovaquone and Azithromycin have been shown to reduce 
tissue cysts in animal models.24  Furthurmore, it penetrates readily into the 
brain tissue.22However the concentration of Azithromycin in the ocular 
tissue is not yet known. 
 
Its efficacy can be attributed to it readily crossing the blood brain and 
blood ocular barrier  being widely distributed in tissues. It can be considered 
in patients who cannot tolerate the side effects of the conventional anti 
toxoplasma medications. 
 
In AIDS patients, the standard regime results in the regression of the 
disease activity, but is associated with severe complications. Approximately, 
40% of the immunocompromised and about 26% of the immunocompetent 
individuals discontinue treatment due to drug toxicity25. Azithromycin, when 
given for protection against disseminated M.avium complex infection in 
AIDS patients, was well tolerated 25. It can be therefore assumed that it will 
be well tolerated by these patients even when they have advanced disease. 
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PREVENTION OF INFECTION 
 
• Meat to be cooked to 60 degrees for at least 15 mins or frozen to 
temperatures below – 20 degrees for at least 24 hours to destroy the 
cysts. 
• Any contact with cat feces to be avoided. 
• Hands to be washed after contact with uncooked meat and after 
contact with cats or soil that could be contaminated with cat feces. 
• Consumption of raw eggs and unpasteurized milk, especially goat’s 
milk to be avoided. 
• Fruits and vegetables to be adequately washed before ingestion. 
• Daily cleaning of cat litter box removes the oocysts before they 
become infectious, because they need 1-3 days after excretion  to 
undergo sporulation. This duty should be only performed by a non 
pregnant individual. 
• Blood transfusions and organ transplants from seropositive donors to 
be avoided if the recipient is seronegative. 
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AIM OF THE STUDY 
 
1. To study the effect of oral Azithromycin on the lesions of ocular 
toxoplasmosis on 50 patients with respect  to 
 
• Reduction in vitreous haze 
• Change in the morphology of the retinal lesion 
• Appearance of any new lesions 
 
2. To compare the characteristics, namely lesion size and its associated 
vitreous haze, of lesions which heal by 6 weeks with those which do 
not heal by 9 weeks. 
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INCLUSION CRITERIA 
1.  Patients with fundal lesions clinically suggestive of ocular toxoplasmosis 
i.e  presence of vitreous cells   and vitreous haze along with active  
retinochoroiditis  lesion with or without an adjacent old scar. 
 
2. Lesions present with the following characterstics: 
• Location  at or around the optic disc, macula, papillomacular  bundle, 
at/near the vascular arcades or 
• Associated with vasculitis or haemorrhage or 
• Lesions presenting with moderate to severe vitritis or 
• Multiple lesions 
3. Patients with a positive serology for antitoxoplasma antibodies (IgM or   
 IgG). 
4. Immunocompetent patients 
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EXCLUSION  CRITERIA 
 
1. Immunocompromised patients 
2. Patients with an active choroiditis lesion but a serology negative for 
toxoplasma infection. 
3. Retinal lesions at locations apart from the abovementioned. 
4. Grade 4 vitreous haze 
5. Patients with other causes of for reduced vision. 
6. History of glaucoma or ocular hypertension. 
7. Uncontrolled diabetes mellitus or hypertension. 
8. Severe systemic disease. 
9. Known hypersensitivity to Azithromycin. 
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10. 
MATERIALS  AND METHODS 
 
This  was a prospective study carried out between March 2009 and 
Sept 2010 in  the department of Uvea services at RIOGOH,Chennai. 
 
 A detailed clinical history was taken from each patient ,the salient 
points of which were 
 
• Clinical symptoms including reduction in visual acuity 
• History  of floaters 
• Pain ,redness and photophobia 
• Any history of fever,rashes,joint pains,ulcers 
• Any of major systemic disorders like Tuberculosis,Diabetes and 
Hypertension 
• History of consumption of undercooked meat or contact with pet 
animals. 
• History of unprotected sexual exposure. 
• Known allergy to any drugs ,especially Azithromycin 
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 The patients were then subjected to a detailed clinical 
examination,both ocular and systemic. Anterior segment examination was 
done using slit lamp biomicroscopy. Posterior segment examination was 
done using 90 D lens and binocular Indirect ophthalmoscope and fundus 
drawing was done. 
 
The following parameters were recorded: 
• Baseline visual acuity and IOP 
• Baseline vitreous haze,retinal lesion location,size and morphology. 
 
The patients were then subjected to the following investigations: 
• Complete blood count 
• Erythrocytic sedimentation rate 
• Mantoux, Chest X-ray 
• VDRL 
• ELISA for HIV 1 and 2 
• TORCH profile 
• RBS 
 
 Patients who were suspected to have toxoplasmosis clinically and 
based on serology were started on antimicrobial therapy. 
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Guidelines for treatment 
• The patients were started on Tab. Azithromycin 500 mg b.d for a period 
of 3 weeks . 
• Oral corticosteroids  - Tab Prednisolone 1mg/kg body weight o.d,  along 
with Tab. Ranitidine 150 mg b.d was started 2 days after starting  
Azithromycin.It was gradually tapered while finishing the course of 
Azithromycin. 
• In the prescence of anterior uveitis   treatment with cycloplegics -2% 
Homotropine b.d and topical corticosteroids –Prednisolone acetate 
eyedrops 6t/day was started and subsequently tapered. 
 
  Guidelines for follow up 
 Patients were required to visit the clinic once a week for a period of 3 
weeks. Thereafter they were supposed to follow up at 6 weeks, 9 weeks and 
at 6 months.The results published are for a period of 6 months of follow up. 
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Main outcome measures 
• Grading of vitreous haze. 
• Retinal lesion size and morphology. 
• Any new retinal lesions. 
 
Best corrected  visual  acuiy( BCVA)  by  Snellen  chart was recorded. 
The treatment with Azithromycin was considered  successful if there was 
absence of intraocular inflammation, if the retinal lesion became flat and 
well demarcated at 6 weeks ,which is the time normally taken for the drug’s 
effect to manifest. Since the disease is mostly self limiting in 
immunocompetent individuals  and normally resolves by 10 weeks , lesions 
which resolved by this time were not included as therapeutic success of the 
drug. 
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OBSERVATION AND RESULTS 
 
Age distribution 
Total no. of patients – 50 
Age distribution No. of patients percentage 
<=20  15 30 
21 - 40 26 52 
41 - 60 7 14 
>60 2 4 
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 Most of the patients in the study were in the age group 21 -40 years 
followed by the group < 20 years and then 41 -60 years. 
Sex distribution 
 
Sex No. of patients percentage 
Male 26 52 
Female 24 48 
 
 
 
 
 
 
The sex distribution of the patients was almost equal with males 
exceeding the females by a marginal 2%. 
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CHIEF OCULAR SYMPTOMS 
 
Symptom No. of patients 
Defective vision 48 
Floaters 19 
Redness, Pain, Photophobia 11 
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The majority of the patients  (66%) complained of defective vision as 
their chief complaint. Floaters were the second most common symptom in 
(19%) of the patients. Pain, redness and photophobia was present in 
15%.These symptoms were not exclusive and many patients presented with 
more than one symptom. 
ANTERIOR SEGMENT INVOLVEMENT 
 
Present Absent 
15 35 
 
 
 
 
30%
70%
0%
Anterior segment involvement
present
absent
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30%
46%
24%
0%
Distribution of vitreous haze
Gr  1
Gr 2
Gr 3
Gr 4
The majority of patients i.e 70% did not have any involvement of the 
anterior segment. 
 
 
 
 
DISTRIBUTION OF VITREOUS HAZE 
Total no. of patients - 50 
Grading of vitreous haze No. of patients 
1 15 
2 23 
3 12 
4 0 
 
. 
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Most of the patients (46%) presented with a vitreous haze of Grade 2 
,followed by Grade 1 (30%) and Grade 3 (24%). Measurement of the vitrous 
haze was done by the comparison chart method of Nussenblatt. 
 
 
LOCATION  OF  THE  RETINOCHOROIDAL  LESION 
Total  no. of eyes studied – 100 
Lesion location No. of  eyes affected 
Macula 22 
Along the papillomacular bundle 3 
Juxtapapillary 4 
Along the vessels 14 
Elsewhere on the retina 4 
Multiple 3 
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Most of the retinochoroidal lesions in this study were located at the 
macula (44%) and along the blood vessels (28%).This was followed by 
lesions at juxtapapillary region and lesions elsewhere on the retina which 
were associated with significant vitreous haze. 
RESULTS OF TREATMENT WITH ORAL AZITHROMYCIN  
 
PRE – TREATMENT VITREOUS HAZE 
 
Vitreous haze grading No. of people Percentage 
1 15 30 
2 23 46 
3 12 24 
 
 
 
POST-TREATMENT VITREOUS HAZE 
 
Vitreous haze grading No. of people Percentage 
0 18 36 
1 12 24 
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2 17 34 
3 3 6 
 
 
 
COMPARISON  BETWEEN PRE AND POST TREATMENT 
 VITREOUS HAZE 
 
 
 
There was a definite reduction in vitreous haze in most of the 
patients.Maximum reduction was seen in the number of people having grade 
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3 haze,reducing from 24% to 6% at 6 weeks.36% of the patients had no 
vitreous haze at 6 weeks. 
 
 
 
 
 
LESION MORPHOLOGY AT 6 WEEKS 
 
 Active lesions Inactive lesions 
No. of people 32 18 
Percentage 64 36 
 
 
  COMPARISON OF LESION MORPHOLOGY AT 6 WEEKS 
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    Out of active ocular lesions in 50 people , 36% of the patients 
experienced conversion of active to inactive lesions at 6 weeks. 
 
 
 
 
PRE-TREATMENT VISUAL ACUITY 
 
Visual Acuity No. of patients Percentage 
<=6/60 19 38 
6/60 – 6/18 24 48 
6/18 – 6/6 7 14 
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                       POST TREATMENT VISUAL ACUITY 
 
Visual Acuity No. of patients Percentage 
<=6/60 7 14 
6/60 – 6/18 25 50 
6/18 – 6/6 18 36 
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COMPARISON BETWEEN PRE AND POST TREATMENT VISUAL 
ACUITY  IN OCULAR TOXOPLASMOSIS 
 
 
 
 
 
There was a distinct improvement in visual acuity of the 
patients.There was a decline in the percentage of people with a visual acuity 
of <=6/60 from 38% to 14%  whereas, people with an acuity between 6/18 to 
6/6 increased from 14% to 36%.The section of people with with visual 
acuity between 6/60 to 6/18 changed marginally from 48% to 50%. 
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EFFICACY OF AZITHROMYCIN 
 
 Lesions healed at 
6 weeks 
Lesions healed at 9 
weeks 
Unhealed lesions 
at 9 weeks 
No. of patients 18 22 
 
10 
 
 
 
CHART SHOWING HEALING TIME OF LESIONS 
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CHARACTERISTICS OF LESIONS HEALED AT 6 WEEKS 
Total  no. of patients - 18 
Lesion size 0.5 dd 1 dd 1.5 dd 2 dd 
No.of patients 1 10 6 1 
 
 
 
Vitreous haze Gr 1 Gr 2 Gr 3 
No. of patients 11 6 
 
1 
 
 
 
Of  the patients whose treatment was considered as therapeutic success 
,56% had a lesion size of 1 dd and only 2% had a size of 2 dd. The majority 
i.e 61% had a vitreous haze of grade 1. 
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        Majority of the patients with healed lesions(56%) had lesions 
corresponding to 1 dd ,followed by 33% with lesions of 1.5dd.Only 6% had 
lesions of 2 dd. 
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Most of the patients in this group (65%) had a vitreous haze of grade 1 
followed by 29% with that of grade 2. 
 
CHARACTERISTICS OF LESIONS NOT RESOLVED AT 9 WEEKS 
 
Total no. of patients - 10 
LESION SIZE 1 dd 1.5 dd 2 dd 2.5 dd 
No. of patients 1 4 4 1 
 
 
 
Vitreous haze Grade 1 Grade 2 Grade 3 
Total no. of 
patients 
1 4 5 
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Out of 10 patients with unresolved lesions even at 9 weeks, 40% had a 
lesion size of 1.5 and 40% of 2 dd. 50% had a vitreous haze of grade 3 and 
40% of grade 2. 
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  Majority of the patients in this group had lesions of size of 1.5 and 2 
dd.(40% each) and 50% had a vitreous haze of grade 3. 
 
 
COMPARISON OF THE LESIONS HEALED AT 6 WEEKS WITH 
LESIONS UNHEALED AT 9 WEEKS 
 
 
 Most of the lesions which healed by 6 weeks (therapeutic effect of the drug) 
were in the range of 1 and 1.5 dd.Most of the lesions which did not heal even 
at 9 weeks were of 1.5 and 2 dd. 
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Most of the lesions healed at 6 weeks were associated with a vitreous 
haze of grade 1 while those which did not heal at 9 weeks had a haze of 
grade 3 mostly. 
DISCUSSION 
 
 Ocular toxoplasmsis is one of the most frequently identified causes of 
uveitis  and Toxoplasma gondii remains the most common organism to 
infect the retina in an otherwise healthy individual.32, 33 
 
This prospective ,non randomized clinical study lasting for one and 
half years was done to evaluate the efficacy of oral Azithromycin the 
treatment of ocular toxoplasmosis. 
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The main  aim was to measure the reduction in intraocular 
inflammation  and change in the morphology of the retinal lesion at the end 
of 6 weeks and to look for recurrence of lesions at new sites at the end of 6 
months.The differences in the characteristics of lesions responding to the 
drug at the end of 6 weeks and those not healing by 9 weeks were also 
studied.Apart from this ,the improvement in visual acuity at the end of 6 
weeks and 9 weeks were also studied. 
  
Out of all the patients included in the study 52% were in the age group 
21 -40 years, 32% in the age group <20 years,12% in the group 41 – 60 years 
and 4% in the group above 60 years. This was in conjunction with a 1973 
publication wherein Perkins  claimed that ocular toxoplasmosis was most 
common in the second and third decades of  life.26 
 
The ratio of males to females was almost equal ,with males being at 
52% and females at 48%.A study done by Rothova et al on 14 patients 
showed similar findings.25 
 
The chief ocular symptom with which the patients presented (66%) 
was defective vision. The reasons for this could be the location at 
macula,macular oedema , large lesion size and prescence of intense 
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inflammation. This was followed by floaters (19%), caused due to opacities 
in the vitreous. Redness, pain and photophobia were present in only in 15% 
of the patients who presented with a spill over anterior uveitis. 
 
The majority of the patients (70%) did not have any anterior segment 
involvement.30% did show some features of involvement of anterior 
segment. 
 
A study done by G.N Holland on 10 patients shows that patients with 
acquired Toxoplasma gondii infection can present with intraocular 
inflammatory reactions without co-existing necrotizing retinal 
lesions.34Therefore this factor should be borne in mind. 
 
Almost half of the patients (40%) had a vitreous haze of grade 
2,followed by 30% having a haze of grade 1 and 24% having grade 3.Since 
vitreous haze is due to a hypersensitivity response along with others like 
anterior uveitis, vasculitis and retinal oedema, it can depend on various 
factors like strain of T. gondii and the host’s immune response. 
 
The most common location of the retinal lesion was the macula(44%) 
followed by that in the vicinity of blood vessels (28%). Juxtapapillary 
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lesions were present in 8% and lesions along the papillomacular bundle in 
6%. Lesions located at locations elsewhwere on the retina were present in 
8% and 6% had multiple lesions. 
 
In another study conducted by Mets, Holfels and Boyer it was found 
that macular lesions occured in over 76% of the patients.29 The increased 
occurrence of lesions at the macula is explained by a number of theories. 
One of them states that fetal vasculature develops first at posterior pole and 
is composed of end arterioles ,so infection is more likely to manifest 
here.Another theory states that the parasite invades the eye through the 
Posterior Ciliary arteries and the optic nerve, therefore the frequent 
involvement of posterior pole.30 
 
Main Outcome measures: 
Vitreous haze:  Intraocular inflammation reduced in a substantial 
number of patients , manifested by a decrease in the vitreous haze. 36% had 
a complete disappearance of inflammation. The number of people with grade 
3 vitreous haze decreased by 18% , grade 2 by 12%, and grade 1 by 
6%.Amongst the patients who manifested active disease at 6 weeks , the 
majority had a haze of grade 2. 
 
79 
 
Retinochoroidal lesion morphology : After 6 weeks of treatment 
36% of the patients displayed inactive lesions ,but 64% still had active 
lesions. The persistently active lesions were associated with a larger initial  
size, more surrounding oedema and greater initial  inflammation in the 
vitreous.  
 
This is supported by a 1993 study conducted in Netherlands on 149 
patients. The patients were divided in four groups.The first group was treated 
with combination of Pyrimethamine, Sulfadiazine, corticosteroids.The 
second with Clindamycin,Sulfadiazine and corticosteroids and the third with 
Trimethoprim ,Sulfamethoxazole and corticosteroids.The last group had 
peripheral lesions and was not put on any treatment. They discovered that 
there was no difference in the duration of inflammatory activity between the 
treated and untreated groups or between separate groups of treated 
patients.Therefore the most important factor predicting the duration of 
inflammatory activity was the size of the lesion itself ,independent of the 
treatment.l24 
 
36% of the active lesions healed in 6 weeks time and these were 
termed as therapeutic success.44% healed in 9 weeks which was attributed to 
the body’s immune mechanism , since this is the time taken by the lesion to 
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heal in an immunocompetent person.20% of the lesions remained active 
even after 9 weeks. 
 
Out of the patients who exhibited a good response to the treatment, 
most (56%) had retinal lesions of smaller size i.e 1 dd or less. The majority 
(65%) had a vitreous haze of grade 1. Only a minority i.e  6% had a lesion 
size of 2 dd or more and a vitreous haze of grade 3.This proved that lesions 
with a smaller size and associated with lesser inflammation  responded better 
to the treatment than those with larger size and more inflammation. 
 
Amongst the patients whose lesions were unresolved even at 9 weeks , 
40%  had a size of 1.5 dd and 40% of  2 or more dd.50%  had a vitreous haze 
of grade 3 and 40% of grade 2. This showed that lesions of larger size and 
associated with greater inflammation  did not respond effectively to the 
treatment.Their natural course went beyond 9 -10 weeks in many cases . 
 
 
Visual acuity(VA) : Visual acuity of many patients showed a definite 
increase at 6 weeks, with 36% of the patients having an acuity between 6/18 
and 6/6.However the majority (50%) had an acuity between 6/60 and 6/18, 
and a small minority still had an acuity of less than 6/60. 
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Most  of the patients in the category where the vision was still 6/60 
either had large macular lesions or those associated with intense 
inflammation. People who had vision between 6/60 and 6/18  included 
mostly those who had macular lesions which healed but resulted in a scar 
leading to persistently diminished vision. In the third category ,most of the 
lesions were located at places other than  the  macula or had a  lesser grade 
of  inflammation. 
 
In a study done on 14 patients with acquired ocular toxoplasmosis, 
Rothova et al  reported a final acuity of less than 20/200 in 6 patients 
because of location of retinal lesion (3 patients), phthisis (2 patients), and 
optic atrophy (1 patient).34 
 
Some of the other complications resulting in reduced vision as 
reported by them include cataract, persistent vitreous opacities, ischemic 
retinal areas, optic nerve atrophy, retinal detachment and phthisis. In the 
1993 study done on 149 patients in Netherlands, it was found that inspite of 
there being a marked reduction in the size of lesions in all the four groups, 
visual acuity before and after treatment did not differ much 
significantly.This was probably due to many lesions being at the macula and 
it being involved in residual scarring.24 
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At the end of 6 months ,there was no recurrence of lesions at newer 
locations. Of the 10 patients with unhealed lesions at 9 weeks ,7 had healed 
by 6 months with scarring, 2 showed evidence of consecutive optic atrophy 
and one still had minimum inflammation in the vitreous. 
 
In the study carried out by Rothova et al , the inference drawn was that 
the risk of recurrence in postnatally acquired toxoplasmosis is 57% within 2 
years. Moreover the recurrence rate increases with the length of follow up. 
Noteworthy was the fact that in five out eight patients with recurrences , 
initial lesions were greater than 3 dd compared to one of six patients without 
any recurrences. Traditionally recurrences have been associated with 
congenital toxoplasmosis34.  
 
A number of hypothetical triggers for reactivation or recurrence have 
been suggested which include, immune response and hormonal status of the 
host, human leukocyte antigen type, autoimmune or hypersensitivity 
reactions against the exposed toxoplasmic antigens and parasite related 
factors such as mechanical rupture of cyst caused by  parasite multiplication 
,release of lytic enzymes by the parasite and reinfection with other parasite 
strains.34 
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In a study carried out on 11 immunocompetent patients of ocular 
toxoplasmosis, treated with Azithromycin 500 mg on day one and followed 
by 250 mg /day for 5 weeks many of whom received additional 
Pyrimethamine, 3 patients developed recurrent lesions at 7, 8 and 9 
months.25 
 
The reason for there being no recurrences in our study  could be 
probably that drug is active against the cyst form as recently proposed20,21 at 
the dose used here. Also all the patients chosen in the study were 
immunocompetent and none of the lesions were as large as 3 dd like the 
study mentioned previously34 Another factor is that 6 months is too short a 
time to comment on the incidence of recurrence and the patients need to be 
followed for a longer time. 
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CONCLUSION 
 
 Ocular toxoplasmosis is a very common disease in immunocompetent  
people and causes significant visual morbidity in a functionally productive 
population. Although mostly self limiting, to date  prevention of recurrent 
attacks is not feasible35. as most of the drugs used are active against the 
tachyzoite form and spare the cyst form. 
 
 Azithromycin 500 mg b.d for a period of 3 weeks  is well tolerated 
and has considerable efficacy in the treatment. In a disease like ocular 
toxoplasmosis which  is essentially self limiting in most immunocompetent 
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individuals, antimicrobials should be prescribed only if truly 
justified.Azithromycin does bring about an earlier resolution (4-6 weeks) in 
a disease which would otherwise last for 10 weeks or longer and handicap 
the person. 
 
However ,it seems that it has better action when the lesions are small 
and inflammation not very  intensive. It is being proposed as one of the 
drugs apart from Atovaquone to be active against the cyst form of the 
parasite  and therefore may prevent recurrences.24 It is also devoid of any 
major side effects  unlike the drugs used in the triple and quadruple 
regime.Azithromycin is also readily available and economically reasonable 
for most patients. All these points that to the fact that it is a reasonable 
alternative to the drugs and at times may even prove better than them. 
 
This study is a small interventional study carried out on a small 
population for a short period of time. In order to judge the drug’s true 
benefits and disadvantages a larger number of people should be followed for 
a longer time. Comparison studies with other treatment modalities are also 
needed. The aspect which needs to be addressed to with greater urgency is 
the prevention of recurrence as it is this which significantly compromises the 
patient’s vision.  
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Finally, it must be emphasised that is no drug is perfect and all have 
their positive and negative aspects. The patient’s response depends not only 
on the  treatment but also on a variety of other factors like the organism’s 
strain, host’s immune response and lesion size.  
 
Therefore keeping all these factors in mind, the disease requires 
greater research into its pathogenesis and  search for a superior treatment.  
 
s 
 
 
 
 
 
PART III 
 
PROFORMA        
PATIENT INFORMATION 
Name                :          
Age         :                    
Sex            :              
Occupation    :         
OP  No.          :         
Address             :     
Phone  No.          :   
 
CHIEF COMPLAINTS 
Defective vision 
Floaters 
Pain, Redness and Photophobia 
Onset  : Acute/Insidius/Chronic                        No. of attacks: 
Systemic history :  Fever/ joint pain/rashes /ulcers/diarrhoea 
Past history   :  TB/Herpes/Diabetes/Hypertension/Trauma 
Personal history  :  Drug allergy/Exposure to pets/Diet (veg/non veg) 
 
 
SYSTEMIC  EXAMINATION: 
CNS  
CVS 
RS 
GIT 
ENT 
SKIN 
GENITOURINARY 
 
OCULAR EXAMINATION  :            RE    LE                          
Visual acuity      :                       
IOP (Applanation)    :                
Conjunctiva      :                         
Cornea     :                                     
Iris               :                               
Anterior chamber      :                  
Lens                                   :         
Anterior Vitreous         : 
       
          
Fundus examination (90 D/IDO)  : 
• Vitreous haze  grading     
• Disc                                   
• Vessels                            
• Macula                              
• Retinal lesion  size         
• Retinal lesion  location   
• Retinal periphery             
• Other features                  
• Diagram                           
 
INVESTIGATIONS 
CBC: 
ESR: 
Mantoux: 
VDRL : 
HIV ELISA: 
TORCH Profile: 
Chest X-ray : 
RBS : 
 
 
 
TREATMENT  given: 
T. Azithromycin 500 mg b.d 
T.Prednisolone 1mg/kg body wt od 
T. Ranitidine 150 mg b.d 
Prednisolone acetate e/d (if  anterior uveitis present) 
2% Homatrpine e/d b.d (if anterior uveitis present) 
 
FOLLOW UP 
       Visual Ac.          Vitreous haze            Retinal lesion                               
Wk 1      
Wk 2 
Wk 3 
Wk 6 
Wk 9 
6 th month 
Recurrence +/- 
 
 
 
 
 
 
 
 
KEY TO MASTER CHART 
 
VA :  Visual  acuity 
 
IOP : Intra ocular pressure 
 
VH :  Vitreous haze 
  
ph  :   pin hole 
 
nip :  not   improving with pin hole 
 
gr :  grade 
 
dd : disc diameter 
 
fl. And dem. : flat and demarcated 
 
Les. Morph : Lesion morphology 
 
MC : Macular choroiditis 
 
VAC: Vessel  associated  choroiditis 
 
PMB  C : Papillomacular bundle region choroiditis 
 
JPC : Juxtapapillary region choroiditis 
 
CE : Choroiditis elsewhere on the retina 
 
MFC : Multifocal choroiditis 
 
OMC :  Old macular choroiditis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST  OF  SURGERIES  PERFORMED 
 
S..no. Name Age Sex Diagnosis IP.  No. Surgeries 
1.  Elangovan 55 M RE  MC/LE 
PSEUDOPH. 
616432 RE ECCE with PCIOL 
2. Jayasheelan 60 M BE  IMC 628288 RE ECCE with PCIOL 
3. Aruna 53 F RE  IMC/LE  MC 624351 LE  ECCE with 
PCIOL 
4. Subramani 48 M RE  CHALAZION 678346 Incision and currettage 
5. Muniammal 57 F BE  IMC 698764 LE  ECCE with 
PCIOL 
6. Lakshmi 62 F BE  MC 615432 RE  ECCE with PI 
7. Mary 54 F RE IMC 626254 LE  ECCE with 
PCIOL 
8. Venkatesh 68 M RE  
ENDOPHTHAL 
658933 RE  Intravitreal 
antibiotics 
9. Babu 50 M LE  IMC 678454 LE  ECCE with 
PCIOL 
10. Chandra 56 F LE  CDC 678456 LE DCT 
11. Kanniappan 72 M RE  MC 645432 RE ECCE with PCIOL 
12. Selvi 38 F RE  EXP. 
KERATITIS 
623543 RE Medial 
Tarsorrhaphy 
13. Abdul . R 52 M LE  IMC/RE 
PSEUDOPH. 
634536 LE  SICS with PCIOL 
14. Dhanalakshmi 65 F BE  IMC 678767 RE SICS  with PCIOL 
15. Sunanda 57 F LE  MC/RE  IMC 645367 LE SICS with PCIOL 
16. Jayammal 68 F BE  IMC 657345 RE  SICS with PCIOL 
17. Lavanya 60 F LE  CDC 657473 LE  DCT 
18. Arulraj 69 M BE  MC 698867 LE  ECCE with 
PCIOL 
19. Varadhan 75 M LE MC/RE  
PSEUDOPH. 
656787 LE  SICS with PCIOL 
20. Sumathy 47 F RE  CDC 619886 RE  DCR 
21. Ranjitham 67 F BE  IMC 654334 RE  SICS with PCIOL 
22. Rani 62 F LE  IMC 678765 LE  SICS with PCIOL 
23. Manickam 75 M RE  MC/LE  
PSEUDOPH. 
687890 RE  SICS 
24. Krishnan 77 M BE  MC 633456 LE  SICS with PCIOL 
25. Ayesha bee 60 F RE  IMC 676547 RE SICS with PCIOL 
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HISTOLOGY  SECTION 
ACUTE  COAGULATIVE  NECROSIS  OF  RETINA 
SECONDARY  DIFFUSE  GRANULOMATOUS  INFLAMMATION  OF  
CHOROID 
 
 
 
TOXOPLASMA  CYSTS  IN NEURAL  RETINA 
 
 ACTIVE  RETINOCHOROIDITIS  WITH  VITRITIS 
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PRE TREATMENT  FUNDUS  PICTURE 
ACTIVE  RETINOCHOROIDITIS  WITH  ILL DEFINED MARGINS  AND  
GRADE  3  VITREOUS  HAZE 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
POST  TREATMENT  FUNDUS  PICTURE  AT  6 WEEKS 
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NAME AGE SEX      DIAGNOSIS VIT.  HAZE
LESION 
SIZE     TREATMENT
New 
lesions
RE LE RE LE RE LE 6 w 9w 6 months
VN VH LES. MORPH VA VH LES. MORPH VA VH LES. MORPH
Mainavati 49 F N m c 6/9 nip 1/60 nip gr 2 2 dd 12 17 T.Azithro 6/60NIP  gr 2 active  6/60nip gr 2 active  6/36 nil fl and dem  nil
Vijay 19 M N jpc  6/6  6/24nip gr 2 1 dd 12 11 T.Azithro  6/24nip gr 2 active  6/18ph6/12 nil  fl. and dem.  6/18ph6/12 nil fl and dem  nil
Kumuda 30 F mc N  6/60nip 6/9ph6/6 gr 3 2 dd 14 12 T.Azithro  6/60NIP gr 2 active  6/36nip gr 1 active  6/36ph6/24 nil fl and dem  nil
Gangadurai 12 M pmb c N 6/36ph6/24  6/6 gr 2 1 dd 16 12 T.Azithro  6/24PH6/18 gr1 active  6/24ph6/18 nil fl. and dem.  6/18nip nil fl and dem  nil
Satish 35 M N va  c  6/12ph6/9  6/12nip gr 1 1.5 dd 13 14 T.Azithro  6/12NIP gr 1 active  6/12ph6/9 gr 1 active  6/12ph6/9 nil fl and dem  nil
Kaniyapan 24 M va  c N 6/24ph6/18  6/6 gr 2 2 dd 15 13 T.Azithro  6/24PH6/18 gr 2 active  6/24ph6/18  gr 1 active  6/24ph6/18 nil fl and dem  nil
Edwin 25 M N va  c  6/6 6/18nip gr 1 1 dd 14 14 T.Azithro  6/18PH6/12 gr 1 active  6/18ph6/9 nil fl. and dem.  6/18ph6/9 nil fl and dem  nil
Asmat. U 20 M o m c va  c  6/36nip  6/36ph6/24 gr 2 1.5 dd 12 12 T.Azithro  6/36NIP gr 2 active  6/36nip  gr 2 active  6/36ph6/24p nil fl and dem  nil
Jyothi 15 F N m c  6/9ph6/6p  4/60nip gr 3 2 dd 14 15 T.Azithro 5/60P gr 2 active  5/60 p  gr 2 active  5/60nip  gr 2 active  nil
Muthulaksmi 17 F N va  c  6/12ph6/9 6/12 nip gr 1 1dd 12 13 T.Azithro  6/9P gr 1 active  6/9ph6/6 nil fl. and dem.  6/9ph6/6 nil fl and dem  nil
Margatham 50 F va  c N  6/24nip  6/12ph6/9 gr 2 1.5 dd 16 17 T.Azithro  6/24ph6/12 gr 2 active  6/24ph6/18  gr 2 active  6/24ph6/18 nil fl and dem  nil
Manti devi 35 F N m c  6/9nip  6/60nip gr 3 2 dd 13 15 T.Azithro  6/60PH6/36 gr 2 active  6/36ph6/24 nil fl. and dem.  6/36ph6/24 nil fl and dem  nil
Indira 29 F N m c  6/6  2/60nip gr 2 2 dd 11 12 T.Azithro  3/60nip gr 2 active  4/60nip  gr 2 active  4/60nip  gr 1 active  nil
Revathi 23 F m c N  6/60nip  6/12ph6/9 gr 3 1.5 dd 15 15 T.Azithro  6/60nip gr 3 active  6/36nip  gr 3 active  5/60nip  gr 2 active  nil
Chitra 26 F N m c  6/6  6/36nip gr 2 2 dd 12 12 T.Azithro  6/36nip gr 2 active  6/24nip  gr 1 active  6/24nip# nil fl and dem  nil
Muthukumar 20 M N m c  6/6p  6/60nip gr 2 3 dd 14 17 T.Azithro  6/60nip gr 1 active  6/36ph6/24  gr 1 active  6/36ph6/24 nil fl and dem  nil
Muthukrishnan 62 M N va  c  6/9ph6/6p  6/12nip gr1 0.5 dd 13 15 T.Azithro  6/12ph6/9 gr 1 active  6/9ph6/6p nil fl. and dem.  6/9ph6/6p nil fl and dem  nil
Ponnamal 35 F N va  c  6/6p  6/36ph6/24 gr 2 1 dd 12 14 T.Azithro  6/36NIP gr 2 active  6/36ph6/24  gr 2 active  6/36ph6/24 nil fl and dem  nil
Elumalai 63 M N va  c  6/9  6/24ph6/18 gr 1 1 dd 16 13 T.Azithro  6/24PH6/18 gr 1 active  6/18ph 6/9 nil fl. and dem.  6/18ph6/9 nil fl and dem  nil
Subhashini 16 F c e N  6/9ph6/6p  6/6 gr 1 1 dd 15 14 T.Azithro  6/9ph6/6 gr 1 active  6/9ph 6/6  gr 1 active  6/9ph6/6# nil fl and dem  nil
Gomati. D 14 F j p c N  6/18nip  6/6 gr 1 1 dd 13 18 T.Azithro  6/12ph6/9 gr 1 active  6/9nip nil fl. and dem.  6/9nip nil fl and dem  nil
Sabri 30 F m c N  6/60nip  6/6p gr 3 2.5 dd 16 17 T.Azithro  6/60nip gr 2 active  6/36pnip  gr 2 active  6/36nip  gr 1 active  nil
Leena 35 F N va  c  6/6p  6/24nip gr 2 2 dd 15 13 T.Azithro  6/24nip gr 1 active  6/24ph6/18  gr 1 active  6/24ph6/18 nil fl and dem  nil
Narayan.S 30 M mult. C N  6/24ph6/18  6/6p gr 2 1-1.5 dd 14 14 T.Azithro  6/24nip gr 2 active  6/24ph6/18p  gr 1 active  6/24ph6/18  gr 1 active  nil
Mahalakshmi 28 F m c N  6/60nip  6/9nip gr 2 2 dd 17 18 T.Azithro  6/36nip gr 2 active  6/36ph6/24p  gr 2 active  6/24nip nil fl and dem  nil
Mani 58 M N m c  6/24nip  6/60nip gr 3 0.5-1 dd 14 12 T.Azithro 6/60nip gr 2 active 6/60 nip  gr 1 active 6/60nip nil fl and dem  nil
Meena 19 F va  c N  6/24ph6/18  6/6 gr 2 1 dd 11 13 T.Azithro  6/12nip gr 1 active  6/12ph6/9 nil fl. and dem.  6/12ph6/9 nil fl and dem  nil
Muthu 29 M N m c  6/6p  3/60p gr 2 2 dd 16 12 T.Azithro  3/60ph5/60 gr 2 active  5/60nip  gr 2 active  5/60nip nil fl and dem  nil
Ram 37 M N c e  6/12ph6/9  6/24ph6/18 gr 1 1.5 dd 14 18 T.Azithro  6/18nip gr 1 active  6/12ph 6/9 nil fl. and dem.  6/12ph6/9 nil fl and dem  nil
Arun 40 M pmb c N  6/36ph6/24  6/18ph6/12 gr2 1 dd 13 12 T.Azithro  6/24nip gr 2 active  6/24nip  gr 2 active  6/24nip  gr 2 active  nil
Tamilselvan 15 M o m c va  c 6/36p 6/18ph6/12 gr 1 1.5 dd 16 12 T.Azithro  6/18ph6/12 gr 1 active  6/12ph6/9 nil fl. and dem.  6/12ph6/9 nil fl and dem  nil
Rathikala 26 F c e o m c  6/24ph6/18  6/60p gr 3 1.5  dd 11 11 T.Azithro  6/24pH6/18 gr 2 active  6/18ph6/12  gr 2 active  6/12nip nil fl and dem  nil
Arumugam 45 M N jpc  6/6  6/24ph6/18 gr 1 1 dd 13 11 T.Azithro  6/18nip gr 1 active  6/12 nip nil fl. and dem.  6/12nip nil fl and dem  nil
Muniammal 40 F N va  c  6/12ph6/6  6/12ph6/9 gr 1 1 dd 18 14 T.Azithro  6/12ph6/9 gr 1 active  6/9ph6/6 nil fl. and dem.  6/9ph6/6 nil fl and dem  nil
Abdul. R 45 M N c e  6/6p  6/24ph6/18 gr 1 1.5 dd 12 13 T.Azithro  6/24ph6/12 gr 1 active  6/12nip nil fl. and dem.  6/12nip nil fl and dem  nil
Ramesh 23 M N m c  6/9ph6/6p  5/60nip gr 3 2 dd 11 13 T.Azithro  5/60nip gr 2 active  6/36nip  gr 2 active  6/36nip  gr 2 active  nil
Ravi 36 M N m c  6/6p  6/36nip gr 2 2 dd 14 13 T.Azithro  6/36ph6/24 gr 2 active   6/24ph6/18  gr 1 active  6/24ph6/18 nil fl and dem  nil
Pushpa 45 F j p c N  6/24nip  6/9ph6/6 gr 2 1 dd 13 15 T.Azithro  6/24nip gr 2 active   6/24ph6/18p nil fl. and dem.  6/12nip nil fl and dem  nil
Pavitra 15 F m c N 4/60nip  6/6 gr 2 2.5dd 16 12 T.Azithro  5/60nip gr 2 active  6/36nip  gr 2 active  6/36nip nil fl and dem  nil
C.Ravi 48 M o m c m c  6/36nip  4/60p gr 3 1.5 dd 14 17 T.Azithro  5/60nip gr 3 active  6/60ph6/36  gr 3 active  6/60ph6/36 nil fl and dem  nil
Munni 40 F N pmb c  6/6p  6/24ph6/18 gr 1 1.5 dd 12 12 T.Azithro  6/18ph6/12 gr 1 active  6/12nip nil fl. and dem.  6/12nip nil fl and dem  nil
Rubavathy 30 F va  c N  6/18nip  6/12ph6/9 gr 2 2 dd 13 12 T.Azithro  6/18PH6/12 gr 2 active  6/18nip  gr 1 active  6/18nip  gr 1 active  nil
Gobi 33 M m c N 2/60nip  6/6 gr 3 2 dd 12 12 T.Azithro 3/60nip gr 3 active  3/60nip  gr 3 active  4/60ph5/60  gr 1 active  nil
Yuvaraj 17 M mult. C N  6/24ph6/18  6/6 gr 1 1-1.5 dd 14 12 T.Azithro  6/18ph6/12 gr 1 active  6/18ph6/12p nil fl. and dem.  6/18ph6/12 nil fl and dem  nil
Malar 29 F m c N 6/36nip 6/9p gr 2 1.5 dd 12 12 T.Azithro  6/36nip gr 2 active  6/36ph6/24  gr 1 active  6/36ph6/24 nil fl and dem  nil
Bhoopalan 20 M m c N 6/60nip  6/12ph6/9 gr 2 1 dd 14 14 T.Azithro  6/60nip gr 2 active  6/36nip  gr 1 active  6/36nip nil fl and dem  nil
Sensaiya 18 M o m c m c  6/36p  6/60nip gr 3 2 dd 13 13 T.Azithro  6/60PH6/36 gr 2 active  6/60ph6/36  gr 2 active  6/36nip nil fl and dem  nil
Geetha 17 F o  c m c  6/6p  6/36nip gr 2 1 dd 13 15 T.Azithro  6/36nip gr 2 active  6/24nip  gr 2 active  6/24nip nil fl and dem  nil
Akash 14 M N va  c  6/18ph6/9  6/12ph6/9 gr 1 1 dd 15 16 T.Azithro  6/12ph6/9 gr 1 active  6/12ph6/6 nil fl. and dem.  6/12ph6/6 nil fl and dem  nil
Narayanswamy 33 M m c N 4/60nip  6/6 gr 3 1.5 dd 11 12 T.Azithro 4/60nip gr 2 active  6/60pnip  gr 2 active  gr 1 active  nil
            IOP
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